These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34400185)

  • 1. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study.
    Devinsky O; Kraft K; Rusch L; Fein M; Leone-Bay A
    J Pharm Sci; 2021 Dec; 110(12):3946-3952. PubMed ID: 34400185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol.
    Kok LY; Bannigan P; Sanaee F; Evans JC; Dunne M; Regenold M; Ahmed L; Dubins D; Allen C
    Eur J Pharm Sci; 2022 Jan; 168():106058. PubMed ID: 34763088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis.
    Kolli AR; Hoeng J
    Cannabis Cannabinoid Res; 2024 Apr; ():. PubMed ID: 38624257
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.
    Cherniakov I; Izgelov D; Domb AJ; Hoffman A
    Eur J Pharm Sci; 2017 Nov; 109():21-30. PubMed ID: 28736128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies.
    Silmore LH; Willmer AR; Capparelli EV; Rosania GR
    Pharmacotherapy; 2021 Apr; 41(4):405-420. PubMed ID: 33583102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb
    Knaub K; Sartorius T; Dharsono T; Wacker R; Wilhelm M; Schön C
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31426272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Cannabidiol in Sprague-Dawley Rats After Oral and Pulmonary Administration.
    Schwotzer D; Kulpa J; Trexler K; Dye W; Jantzi J; Irshad H; Ware MA; Bonn-Miller M; McDonald J; Lefever T
    Cannabis Cannabinoid Res; 2023 Apr; 8(2):360-373. PubMed ID: 36301522
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
    Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
    Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers.
    Izgelov D; Davidson E; Barasch D; Regev A; Domb AJ; Hoffman A
    Eur J Pharm Biopharm; 2020 Sep; 154():108-115. PubMed ID: 32634571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications.
    Perucca E; Bialer M
    CNS Drugs; 2020 Aug; 34(8):795-800. PubMed ID: 32504461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Intramuscular Bioavailability of Cannabidiol Using Nanocrystals: Formulation, In Vitro Appraisal, and Pharmacokinetics.
    Fu X; Xu S; Li Z; Chen K; Fan H; Wang Y; Xie Z; Kou L; Zhang S
    AAPS PharmSciTech; 2022 Mar; 23(3):85. PubMed ID: 35288801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations.
    Franco V; Gershkovich P; Perucca E; Bialer M
    Clin Pharmacokinet; 2020 Dec; 59(12):1493-1500. PubMed ID: 32785853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.
    Cherniakov I; Izgelov D; Barasch D; Davidson E; Domb AJ; Hoffman A
    J Control Release; 2017 Nov; 266():1-7. PubMed ID: 28890215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
    Atsmon J; Heffetz D; Deutsch L; Deutsch F; Sacks H
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):751-758. PubMed ID: 29125702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.